• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Anecortave acetate found to safe, effective for inhibiting CNV growthin AMD patients

Article

Anecortave acetate (Retaane), a potent angiostatic agent, has been shownto be safe and superior to placebo in reducing loss of vision from baseline,avoiding severe vision loss, and inhibiting the growth of CNV membranesin patients with age-related macular degeneration (AMD), reported JasonS. Slakter, MD, who spoke during the American Academy of Ophthalmology annualmeeting.

Related Videos
EyeCon 2024: Peter J. McDonnell, MD, marvels on mentoring, modern technology, and ophthalmology’s future
Lorraine Provencher, MD, presenting slides
Katherine Talcott, MD, presenting slides
Katherine Talcott, MD, presenting slides
© 2024 MJH Life Sciences

All rights reserved.